Notify me when 683 Capital Management, LLC files a new 13F portfolio report.
⭐ Subscribe ⭐| Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Filing Time |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 205 | $1,202,555,019 | +$235,402,519 | -$250,999,547 | -$15,597,028 | COF, WVE, CVNA, BRIDGEBIO PHARMA INC, GXO | 13F-HR | 17 Feb 2026, 09:09 |
| Q3 2025 | 117 | $1,100,796,049 | +$128,499,671 | -$237,176,637 | -$108,676,966 | COF, QURE, CVNA, UWMC, GXO | 13F-HR | 14 Nov 2025, 09:40 |
| Q2 2025 | 116 | $986,089,818 | +$186,634,955 | -$282,697,781 | -$96,062,826 | COF, CVNA, GXO, AMTM, HGV | 13F-HR | 14 Aug 2025, 09:02 |
| Q1 2025 | 119 | $985,673,780 | +$235,921,215 | -$198,881,008 | +$37,040,207 | COF, GXO, INSMED INC, CVNA, WVE | 13F-HR | 15 May 2025, 10:08 |
| Q4 2024 | 210 | $1,016,397,419 | +$181,664,728 | -$152,581,512 | +$29,083,216 | COF, WVE, CVNA, HGV, INSMED INC | 13F-HR | 14 Feb 2025, 12:14 |
| Q3 2024 | 129 | $981,789,809 | +$108,328,754 | -$181,919,246 | -$73,590,492 | COF, ERO, HGV, CVNA, INSMED INC | 13F-HR | 14 Nov 2024, 16:01 |
| Q2 2024 | 131 | $953,109,957 | +$150,609,551 | -$133,412,928 | +$17,196,623 | HGV, COF, SN, ERO, BWA | 13F-HR | 14 Aug 2024, 16:14 |
| Q1 2024 | 122 | $979,705,963 | +$123,000,270 | -$287,028,947 | -$164,028,677 | HGV, COF, ERO, SN, BWA | 13F-HR | 15 May 2024, 16:11 |
| Q4 2023 | 240 | $998,821,996 | +$173,620,769 | -$244,492,995 | -$70,872,226 | BWA, COF, ERO, HGV, SN | 13F-HR | 14 Feb 2024, 16:08 |
| Q3 2023 | 135 | $986,426,380 | +$209,410,244 | -$234,077,799 | -$24,667,555 | ENVA, ERO, COF, OXYWS, WVE | 13F-HR | 14 Nov 2023, 16:41 |
| Q2 2023 | 144 | $1,028,377,486 | +$210,689,266 | -$387,492,622 | -$176,803,356 | ENVA, ERO, COF, BWA, NE | 13F-HR | 14 Aug 2023, 16:39 |
| Q1 2023 | 271 | $1,115,808,459 | +$196,251,672 | -$228,624,427 | -$32,372,755 | ENVA, ERO, OXYWS, COF, NE | 13F-HR | 15 May 2023, 14:08 |
| Q4 2022 | 296 | $1,109,419,165 | +$204,654,947 | -$355,930,212 | -$151,275,265 | ENVA, ERO, WVE, OXYWS, HES | 13F-HR | 14 Feb 2023, 14:43 |
| Q3 2022 | 235 | $1,237,178,000 | +$122,248,619 | -$246,390,477 | -$124,141,858 | ENVA, ERO, IAC, LEN, HES | 13F-HR | 14 Nov 2022, 15:20 |
| Q2 2022 | 264 | $1,382,784,000 | +$242,706,373 | -$204,626,373 | +$38,080,000 | ENVA, IAC, OPEN, CVNA, GM | 13F-HR | 15 Aug 2022, 14:03 |
| Q1 2022 | 345 | $1,689,823,000 | +$407,151,436 | -$550,719,414 | -$143,567,978 | ENVA, CVNA, CDLX, OPEN, IAC | 13F-HR | 16 May 2022, 14:30 |
| Q4 2021 | 331 | $2,099,780,000 | +$608,908,701 | -$336,288,324 | +$272,620,377 | CVNA, ENVA, OPEN, HLF, CDLX | 13F-HR | 14 Feb 2022, 14:21 |
| Q3 2021 | 202 | $1,928,627,000 | +$518,367,137 | -$421,134,666 | +$97,232,471 | CVNA, CDLX, ENVA, FE, HLF | 13F-HR | 15 Nov 2021, 14:12 |
| Q2 2021 | 186 | $2,013,655,000 | +$617,735,281 | -$226,596,122 | +$391,139,159 | CVNA, CDLX, FE, ENVA, HLF | 13F-HR | 16 Aug 2021, 14:00 |
| Q1 2021 | 151 | $1,546,532,000 | +$430,496,957 | -$546,833,451 | -$116,336,494 | CVNA, ENVA, FE, IAC, MMP | 13F-HR | 17 May 2021, 14:05 |
| Q4 2020 | 194 | $1,569,650,000 | +$347,887,787 | -$172,324,539 | +$175,563,248 | CVNA, FE, CDLX, ENVA, MMP | 13F-HR | 16 Feb 2021, 14:23 |
| Q3 2020 | 129 | $1,076,045,000 | +$321,543,802 | -$403,559,391 | -$82,015,589 | CVNA, CDLX, FE, IAC, MMP | 13F-HR | 16 Nov 2020, 14:08 |
| Q2 2020 | 129 | $992,303,000 | +$215,221,030 | -$197,455,699 | +$17,765,331 | IAC, CVNA, CDLX, AMZN, COF | 13F-HR | 14 Aug 2020, 14:00 |
| Q1 2020 | 135 | $645,506,000 | +$278,116,576 | -$42,674,236 | +$235,442,340 | CVNA, IAC, CDLX, COF, GRUB | Restatement | 15 May 2020, 15:38 |
| Q4 2019 | 157 | $628,947,000 | +$119,092,207 | -$212,717,537 | -$93,625,330 | CVNA, CDLX, QURE, EIGR, ALNY | 13F-HR | 14 Feb 2020, 14:48 |
| Q3 2019 | 136 | $600,788,000 | +$76,922,152 | -$164,386,338 | -$87,464,186 | CVNA, ALNY, NIHD, RDHL, HOME | 13F-HR | 14 Nov 2019, 13:38 |
| Q2 2019 | 155 | $766,387,000 | +$71,526,937 | -$74,108,727 | -$2,581,790 | CVNA, PCG, QURE, STNG, ALNY | 13F-HR | 14 Aug 2019, 16:18 |
| Q1 2019 | 149 | $745,666,000 | +$108,565,257 | -$109,288,070 | -$722,813 | CVNA, PCG, QURE, RDHL, ALNY | 13F-HR | 15 May 2019, 14:03 |
| Q4 2018 | 159 | $672,126,000 | +$200,493,413 | -$85,695,886 | +$114,797,527 | CVNA, NIHD, TRVG, TRUE, QURE | Restatement | 15 Feb 2019, 15:30 |
| Q3 2018 | 136 | $802,900,000 | +$106,626,272 | -$147,939,485 | -$41,313,213 | CVNA, NIHD, TRUE, ADNT, QURE | 13F-HR | 14 Nov 2018, 16:21 |
| Q2 2018 | 130 | $767,745,000 | +$145,064,687 | -$125,806,120 | +$19,258,567 | CVNA, NIHD, ADNT, QURE, TRUE | Restatement | 17 Sep 2018, 16:53 |
| Q1 2018 | 122 | $668,234,000 | +$168,146,836 | -$158,703,461 | +$9,443,375 | ADNT, PCG, TRUE, CVNA, NIHD | 13F-HR | 15 May 2018, 14:37 |
| Q4 2017 | 123 | $627,409,000 | +$212,279,464 | -$159,802,538 | +$52,476,926 | ADNT, PCG, ALNY, NYRT, KKR | Restatement | 05 Mar 2018, 16:35 |
| Q3 2017 | 99 | $555,500,000 | +$132,144,111 | -$86,715,878 | +$45,428,233 | ADNT, KKR, ALNY, AABA, CARS | Restatement | 07 Dec 2017, 15:02 |
| Q2 2017 | 80 | $466,286,000 | +$146,114,530 | -$127,190,159 | +$18,924,371 | ADNT, KKR, ALNY, AGN, CRESY | 13F-HR | 14 Aug 2017, 14:43 |
| Q1 2017 | 62 | $425,785,000 | +$106,231,673 | -$152,811,086 | -$46,579,413 | EEM, KKR, ADNT, CRESY, AGN | 13F-HR | 15 May 2017, 14:51 |
| Q4 2016 | 63 | $411,763,000 | +$164,610,742 | -$56,468,219 | +$108,142,523 | FXI, KKR, ADNT, EWT, GS | Restatement | 07 Dec 2017, 15:02 |
| Q3 2016 | 61 | $290,951,000 | +$85,844,373 | -$56,926,032 | +$28,918,341 | KKR, CRESY, SQBG, MU, SUPERNUS PHARMACEUTICALS INC | 13F-HR | 14 Nov 2016, 14:52 |
| Q2 2016 | 47 | $229,007,000 | +$75,662,641 | -$158,662,370 | -$82,999,729 | EMC, SNR, CRESY, MU, KKR | 13F-HR | 15 Aug 2016, 14:12 |
| Q1 2016 | 47 | $300,531,000 | +$128,022,853 | -$136,466,494 | -$8,443,641 | EEM, RITM, SNR, MU, KKR | 13F-HR | 16 May 2016, 14:38 |
| Q4 2015 | 76 | $315,115,000 | +$92,778,654 | -$37,590,112 | +$55,188,542 | NRK, RITM, MU, SNR, SUPERNUS PHARMACEUTICALS INC | 13F-HR | 16 Feb 2016, 15:21 |
| Q3 2015 | 62 | $265,215,000 | +$87,705,197 | -$41,956,847 | +$45,748,350 | EEM, MU, NRK, SUPERNUS PHARMACEUTICALS INC, SNR | 13F-HR | 16 Nov 2015, 16:07 |
| Q2 2015 | 55 | $253,172,000 | +$86,769,827 | -$59,251,005 | +$27,518,822 | NRK, CAR, SUPERNUS PHARMACEUTICALS INC, EEM, LUK | 13F-HR | 14 Aug 2015, 16:07 |
| Q1 2015 | 51 | $218,952,000 | +$100,121,693 | -$52,125,849 | +$47,995,844 | NRK, SUPERNUS PHARMACEUTICALS INC, CPN, XHR, LUK | 13F-HR | 15 May 2015, 12:09 |
| Q4 2014 | 40 | $158,314,000 | +$46,609,093 | -$91,311,095 | -$44,702,002 | NRK, SUPERNUS PHARMACEUTICALS INC, LUK, AMTRUST FINL SVCS INC, JOY | 13F-HR | 17 Feb 2015, 08:45 |
| Q3 2014 | 43 | $208,153,000 | +$48,410,664 | -$40,315,164 | +$8,095,500 | NRK, F113PS, LUK, CSH, GEVO INC | 13F-HR | 14 Nov 2014, 12:00 |
| Q2 2014 | 44 | $206,127,000 | +$39,221,961 | -$41,248,782 | -$2,026,821 | NRK, SBGL, NWS, RHP, GEVO INC | 13F-HR | 14 Aug 2014, 16:09 |
| Q1 2014 | 43 | $189,839,000 | +$64,108,918 | -$62,055,645 | +$2,053,273 | NRK, GEVO INC, EXAS, NWS, RHP | 13F-HR | 15 May 2014, 16:31 |
| Q4 2013 | 42 | $179,778,000 | $0 | $0 | $0 | NRK, GEVO INC, NWS, AIG, EXAS | 13F-HR | 14 Feb 2014, 16:32 |